This study is exploring a new treatment for adults with certain types of blood cancer, called B-cell acute lymphoblastic leukemia (ALL) or B-cell lymphoblastic lymphoma (LBL). The new treatment combines a drug called inotuzumab ozogamicin with lower doses of traditional chemotherapy. Inotuzumab ozogamicin is a special medicine that finds and attacks cancer cells, thanks to a part called a monoclonal antibody. This study compares this new combination to regular chemotherapy to see which works better.

• Participants are placed in one of two groups: one receiving the new treatment and the other receiving standard chemotherapy.
• The study lasts up to two years, with regular checkups to monitor progress and health.
• Patients will have follow-up visits every few months after completing the treatment.

Eligible participants must be 50 years or older, have a confirmed diagnosis of B-cell ALL or LBL, and meet specific health criteria. The study aims to measure how well the cancer responds to the treatment and check for any side effects. Be sure to discuss with your doctor if you are interested in participating, to understand potential benefits and risks.